Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease
Bram Verstockt(Universitair Ziekenhuis Leuven), Séverine Vermeire(KU Leuven), Vipul Jairath(Western University), William A. Faubion(Mayo Clinic in Arizona), Stefania Vetrano(Fondazione Humanitas per la Ricerca), William J. Sandborn(University of San Diego), Dermot McGovern(Salford Royal NHS Foundation Trust), Azucena Salas(Hospital Clínic de Barcelona), Julián Panés(Hospital Clínic de Barcelona), Silvio Danese(IRCCS Ospedale San Raffaele), Brian G. Feagan(Western University), Niels Vande Casteele(University of California San Diego), Geert D’Haens(Amsterdam University Medical Centers), Shadi Nayeri(Lunenfeld-Tanenbaum Research Institute), Marjolijn Duijvestein(Amsterdam University Medical Centers), Mark S. Silverberg(Sinai Health System), Christopher Ma(University of Calgary), Lars Eckmann(University of San Diego)
Cited by 134
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k